Items Tagged ‘Recurrent Multiple Myeloma’

November 29th, 2016

Darzalex® Approved for Additional Indications in Multiple Myeloma

By

The United States Food and Drug Administration (FDA) has approved Darzalex® (daratumumab) for the treatment of multiple myeloma among patients who have received at least one prior therapy. The new FDA indication also requires that daratumumab be used in combination with lenalidomide and dexamethasone, or in combination with bortezomib and dexamethasone. Daratumumab is already approved […]

View full entry

Tags: blood cancer, bortezomib, CASTOR, CD38, Darzalex, dexamethasone, fda, lenalidomide, Multiple Myeloma, News, POLLUX, Recurrent Multiple Myeloma


July 7th, 2016

Darzalex™ Effective in Heavily Pre-Treated Multiple Myeloma

By

The targeted agent Darzalex (daratumumab) produces long-lasting anti-cancer responses among patients with multiple myeloma that has stopped responding to several prior therapies. These results were recently published in the journal Blood. Multiple myeloma is a type of blood cancer that affects certain immune cells called plasma cells. Healthy plasma cells produce proteins called antibodies that […]

View full entry

Tags: blood cancer, daratumumab, Darxalex, IMid, Multiple Myeloma, News, PI, proteasome inhibitor, Recurrent Multiple Myeloma, Stages II-III Multiple Myeloma


April 21st, 2016

Aplidin® Improves Progression-Free Survival in Multiple Myeloma

By

The addition of the investigative agent Aplidin® (plitidepsin) to dexamethasone appears to significantly reduce the risk of cancer progression or death compared to dexamethasone alone among patients with multiple myeloma that has progressed following prior therapies. Multiple myeloma is a type of blood cancer that affects certain immune cells called plasma cells. Healthy plasma cells […]

View full entry

Tags: ADMYRE, Aplidin, ascidian Aplidium albicans, blood cancer, Multiple Myeloma, News, plasma cells, Plitidepsin, Recurrent Multiple Myeloma


January 26th, 2016

Combo Therapy of Kyprolis plus Dexamethasone Approved for Recurrent Multiple Myeloma

By

The United States Food and Drug Administration (FDA) recently approved a new treatment combination consisting of Kyprolis (carfilzomib) plus dexamethasone for patients with relapsed or refractory multiple myeloma. Multiple myeloma is a type of blood cancer that affects certain immune cells called plasma cells. Healthy plasma cells produce proteins called antibodies that are an important […]

View full entry

Tags: carfilzomib, dexamethasone, ENDEAVOR, fda, kyprolis, Multiple Myeloma, News, Recurrent Multiple Myeloma


December 31st, 2015

Leukemia and Lymphoma Society Summarizes Major Advances in Treatment of Blood Cancers Presented at American Society of Hematology Meetings

By

For the more than one million Americans living with or in remission from a blood cancer, there is more hope than ever for new treatments and even cures—not someday, but today. Clinical findings presented at the 57th American Society of Hematology (ASH) Annual Meeting, in Orlando, December 5-8, made it increasingly clear that new discoveries […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, all, AML, ASH, blood cancer, CAR T, Chronic Lymphocytic Leukemia, CLL, fda, Leukemia, Lymphoma


December 7th, 2015

FDA Approves Empliciti for Multiple Myeloma

By

The United States Food and Drug Administration (FDA) has approved Empliciti (elotuzumab) for the treatment of patients with multiple myeloma who have received prior therapies. The indication specifies that Empliciti is to be used in combination with lenalidomide and dexamethasone for the treatment of patients who have received one to three prior therapies for multiple […]

View full entry

Tags: dexamethasone, elotuzumab, Empliciti, fda, lenalidomide, Multiple Myeloma, News, Recurrent Multiple Myeloma, SLAMF7


November 23rd, 2015

Ninlaro® Approved for Multiple Myeloma

By

The United States Food and Drug Administration (FDA) has granted approval to Ninlaro® (ixazomib) for the treatment of multiple myeloma. This marks the third drug approved this year for the treatment of multiple myeloma. The approval specifies that Ninlaro is to be used in addition to two other agents, Revlimid (lenalidomide) and dexamethasone, to treat […]

View full entry

Tags: fda, Multiple Myeloma, News, ninlaro, Recurrent Multiple Myeloma


November 17th, 2015

FDA Approves Darzalex Providing a New Treatment for Patients with Multiple Myeloma

By

Today the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma. Darzalex is the first monoclonal antibody approved for treating multiple myeloma. Darzalex appears to be effective in patients with multiple myeloma that has stopped responding to standard therapies according to study results recently published in the […]

View full entry

Tags: Darzlex, monoclonal antibody, Multiple Myeloma, News, Recurrent Multiple Myeloma


September 17th, 2015

Daratumumab Effective in Multiple Myeloma

By

The targeted agent, daratumumab, which is still in clinical trials, appears to be effective in patients with multiple myeloma that has stopped responding to standard therapies. These results were recently published in the New England Journal of Medicine. Multiple myeloma is a cancer of plasma cells, which are a special type of white blood cell […]

View full entry

Tags: clinical trial, daratumumab, Multiple Myeloma, News, Recurrent Multiple Myeloma, refactory


September 2nd, 2015

Immunotherapy Benefits Patients with Drug-Resistant Multiple Myeloma

By

In its first clinical trial, a breakthrough antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments, investigators at Dana-Farber Cancer Institute and other organizations report today online in the New England Journal of Medicine. The drug, daratumumab, proved generally safe in patients even […]

View full entry

Tags: antibody therapy, clinical trial, daratumumab, monoclonal antibody, Multiple Myeloma, News, Recurrent Multiple Myeloma


February 25th, 2015

Farydak® Approval Provides Another Treatment Option for Patients With Multiple Myeloma

By

Novartis announced today that the US Food and Drug Administration (FDA) has approved Farydak® (panobinostat) in combination with Velcade® and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior regimens, including Velcade® and an immunomodulatory (IMiD) agent. The FDA approval was partially based on the results of the […]

View full entry

Tags: bortezomib, farydak, Multiple Myeloma, News, panobinostat, Recurrent Multiple Myeloma, velcade


January 26th, 2015

Further Findings Show Pomalyst plus Low-Dose Dexamethasone Safe and Effective in Relapsed or Refractory Multiple Myeloma

By

For patients with relapsed or refractory multiple myeloma, treatment with Pomalyst® (pomalidomide) plus low-dose dexamethasone appears safe and effective. These findings were presented at the 56th American Hematological Society Annual Meeting and Exposition, December 6–9, 2014, in San Francisco, California.[1] Multiple myeloma is a cancer of plasma cells, which are a special type of white […]

View full entry

Tags: Multiple Myeloma, News, pomalidomide, pomalyst, Recurrent Multiple Myeloma, refractory


December 15th, 2014

Daratumumab Anti-CD38 Monoclonal Antibody Appears Promising For the Treatment of Multiple Myeloma

By

An investigational new class of drugs, the anti-CD38 monoclonal antibodies, could be the next major advance in the treatment of multiple myeloma. These findings were presented at the 56th American Hematological Society Annual Meeting and Exposition, December 6–9, 2014, in San Francisco, California. Multiple myeloma is a cancer of plasma cells, which are a special […]

View full entry

Tags: anti-CD38, daratumumab, Multiple Myeloma, News, Recurrent Multiple Myeloma


December 10th, 2014

Imbruvica® Demonstrates Clinical Activity in Relapsed or Refractory Multiple Myeloma

By

According to new data reported at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition, Imbruvica® (ibrutinib) demonstrated activity in the treatment of patients with relapsed or relapsed/refractory multiple myeloma. Multiple myeloma is a cancer of plasma cells. Plasma cells are a special type of white blood cell that are part of the […]

View full entry

Tags: imbruvica, Multiple Myeloma, News, Recurrent Multiple Myeloma


December 9th, 2014

SAR 650948 Anti-CD38 Monoclonal Antibody Appears Promising For the Treatment of Multiple Myeloma

By

An investigational new class of drugs, the anti-CD38 monoclonal antibodies, could be the next major advance in the treatment of multiple myeloma. These findings were presented at the 56th American Hematological Society Annual Meeting and Exposition, December 6–9, 2014, in San Francisco, California. Multiple myeloma is a cancer of plasma cells, which are a special […]

View full entry

Tags: Multiple Myeloma, News, Recurrent Multiple Myeloma, SAR, SAR 650984